Advanced Medical Solutions Grp PLC Notice of Results (7883P)
14 Febbraio 2023 - 8:01AM
UK Regulatory
TIDMAMS
RNS Number : 7883P
Advanced Medical Solutions Grp PLC
14 February 2023
14 February 2023
Advanced Medical Solutions Group plc
("AMS" or the "Group")
Notice of Preliminary Results
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS),
the world-leading specialist in tissue-healing technologies, will
announce its preliminary results for the twelve months ended 31
December 2022 on Wednesday 15 March 2023.
A briefing for analysts will be held at 10am GMT on the day of
the results. For further information, please contact
AMS@consilium-comms.com .
- End -
For further information, please contact:
Advanced Medical Solutions Group plc Tel: +44 (0) 1606
545508
Chris Meredith, Chief Executive Officer
Eddie Johnson, Chief Financial Officer
Michael King, Investor Relations
Consilium Strategic Communications Tel: +44 (0) 20 3709
5700
Matthew Neal / Lucy Featherstone
Investec Bank PLC (NOMAD & Broker) Tel: +44 (0) 20 7597
5970
Gary Clarence/ David Anderson
HSBC Bank PLC (Broker) Tel: +44 (0) 20 7991
8888
Sam McLennan / Joe Weaving / Stephanie
Cornish
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of
innovative tissue-healing technology, focused on quality outcomes
for patients and value for payers. AMS has a wide range of surgical
products including tissue adhesives, sutures, haemostats, internal
fixation devices and internal sealants, which it markets under its
brands LiquiBand(R) , RESORBA(R) , LiquiBandFix8(R) and Seal-G(R) .
AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(R) brand as well as under
white label. Since 2019, the Group has made four acquisitions:
Sealantis, an Israeli medical device company with a
patent-protected sealant technology platform; Biomatlante, an
established French developer and manufacturer of innovative
surgical biomaterial technologies, Raleigh, a UK leading coater and
converter of materials predominately for woundcare and
bio-diagnostics products and AFS Medical, an Austrian a specialist
surgical business with a focus on minimally invasive
procedures.
AMS's products, manufactured in the UK, Germany, France, the
Netherlands, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as
well as via AMS's own direct sales forces in the UK, Germany,
Austria, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Germany, France and Israel. Established
in 1991, the Group has more than 700 employees. For more
information, please see www.admedsol.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORGPUBWPUPWGBW
(END) Dow Jones Newswires
February 14, 2023 02:01 ET (07:01 GMT)
Grafico Azioni Advanced Medical Solutions (AQSE:AMS.GB)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Advanced Medical Solutions (AQSE:AMS.GB)
Storico
Da Mag 2023 a Mag 2024
